SEC Filing: Form 4
Statement of changes in beneficial ownership of securities
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Statement of changes in beneficial ownership of securities
Statement of acquisition of beneficial ownership by individuals – amendment
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX114 expected by year end and VYN201 and VYN202 to enter the clinic in 2022 Company has prepaid the entirety of its outstanding debt and expects to significantly reduce operating expenses Conference call and live webcast today at 8:30 am Eastern Time BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the second quarter…